Management of Heart Failure Patients with COVID-19. A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology.
机构：[1]Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China[2]Department of Cardiology, IRCCS San Raffaele Pisana, Rome, Italy[3]Department of Cardiovascular Surgery, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China[4]Cardiology, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy[5]Division of Cardiology, University of Perugia School of Medicine, Perugia, Italy[6]Department of Cardiology (CVK),and Berlin Institute of Health Center for Regenerative Therapies (BCRT),German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany[7]Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA[8]Key Laboratory for Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China[9]First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China[10]Department of Medicine, Cook County Hospital, Chicago, IL, USA[11]Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China[12]Université de Paris, Paris, France,U942 Inserm – MASCOT and Department of Anaesthesia and Critical Care, University Hospitals Saint Louis-Lariboisière, APHP, Paris, France[13]Center for Heart Diseases, University Hospital, Medical University, Wroclaw, Poland[14]Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute, Wuhan University, Hubei Key Laboratory of Cardiology, Wuhan, China[15]University Heart Centre, University Hospital Zurich, Zurich, Switzerland[16]Clinic of Endocrinology, Diabetes and Metabolic Diseases, Belgrade University Medical Center, Belgrade, Serbia[17]Department of Cardiology, Campus Virchow Klinikum, Charite - Universitaetsmedizin Berlin, Berlin, Germany[18]Department of Cardiology, Peking Union Medical College & Chinese Academy of Medical Science, Peking Union Medical College Hospital, Beijing, China[19]Department of Cardiology, Henan Provincial People’s Hospital, Fuwai Central China Cardiovascular Hospital, Zhengzhou, China[20]Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, China[21]Cardiology Division, Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy
The Coronavirus Disease 2019 (COVID-19) pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is causing considerable morbidity and mortality worldwide. Multiple reports have suggested that patients with heart failure (HF) are at a higher risk of severe disease and mortality with COVID-19. Moreover, evaluating and treating HF patients with comorbid COVID-19 represents a formidable clinical challenge as symptoms of both conditions may overlap and they may potentiate each other. Limited data exist regarding comprehensive management of HF patients with concomitant COVID-19. Since these issues pose serious new challenges for clinicians worldwide, HF specialists must develop a structured approach to the care of patients with COVID-19 and be included early in the care of these patients. Therefore, the Heart Failure Association of the European Society of Cardiology and Chinese Heart Failure Association & National Heart Failure Committee conducted web-based meetings to discuss these unique clinical challenges and reach a consensus opinion to help providers worldwide deliver better patient care. The main objective of this position paper is to outline the management of HF patients with concomitant COVID-19 based on the available data and personal experiences of physicians from Asia, Europe and United States. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
基金：
A.J.S.C. reports honoraria and/or lecture
fees from AstraZeneca, Bayer, Menarini, Novartis, Nutricia,
Servier, Vifor, Actimed, Cardiac Dimensions, CVRx, Enopace,
Faraday, Gore, Impulse Dynamics, Respicardia, Stealth Peptides,
V-Wave, Corvia, Arena, ESN Cleer. G.A. consultant to Menarini
International, Servier International, Merck, Angelini, Boehringer;
grant support Menarini International; lectures for Menarini International,
Merck, and Boeheringer. S.D.A. reports receiving fees from
Bayer, Boehringer Ingelheim, Cardiac Dimension, Impulse Dynamics,
Novartis, Servier, St. Jude Medical and Vifor Pharma, and grant
support from Abbott Vascular and Vifor Pharma. J.B. declares that
he serves as a consultant for Abbott, Adrenomed, Amgen, Array,
AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb,
CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen,
LivaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordisk,
Relypsa, Roche, V-Wave Limited, and Vifor. A.M. receives speaker
honoraria from Abbott, Orion, Roche and Servier and fee from
BMS, Adrenomed, Neurotronik, Roche, Sanofi and Sphyngotec.
FR reports grant support for the ESC-HFA Postgraduate Course
in Heart Failure from Novartis, Servier, Bayer, Abbott and Astra
Zeneca and the VASCEND trial from Novartis (all payments
directly to the University of Zurich). FR has been paid for the time
spent as a committee member for clinical trials, advisory boards,
other forms of consulting and lectures or presentations. These
payments were made directly to the University of Zurich and no
personal payments were received in relation to these trials or other
activities since January 2018. Before 2018 FR reports grants and
personal fees from SJM / Abbott, Servier, Novartis and Bayer, personal
fees from Zoll, Astra Zeneca, Sanofi, Amgen, BMS, Pfizer,
Fresenius, Vifor, Roche, Cardiorentis and Boehringer Ingelheim,
other from Heartware and grants from Mars, outside the submitted
work. P.S. reports honoraria for lectures from Medtronic,
Abbott, Servier, AstraZeneca, Respicardia; consultancy agreement
and honoraria for lectures from Boehringer Ingelheim, Novartis;
and consultancy agreement for Vifor Pharma. M.S. receives consulting
fees from Novartis, Bayer, Abbott, Merck, Vifor Pharma,
AstraZeneca, and Boehringer Ingelheim. M.M. reports receiving
fees from Abbott Vascular, Amgen, AstraZeneca, Bayer, Edwards
Therapeutics, Fresenius, Vifor, and Windtree Therapeutics as participant
to trials’ committees or advisory boards or for lectures.
All other authors have nothing to disclose.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类|1 区医学
小类|1 区心脏和心血管系统
最新[2025]版：
大类|1 区医学
小类|1 区心脏和心血管系统
第一作者：
第一作者机构：[1]Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
通讯作者：
通讯机构：[1]Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China[4]Cardiology, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy[*1]Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China.[*2]Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
推荐引用方式(GB/T 7714)：
Yuhui Zhang,Andrew J.S. Coats,Zhe Zheng,et al.Management of Heart Failure Patients with COVID-19. A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology.[J].European journal of heart failure.2020,22(6):941-956.doi:10.1002/ejhf.1915.
APA：
Yuhui Zhang,Andrew J.S. Coats,Zhe Zheng,Marianna Adamo,Giuseppe Ambrosio...&Marco Metra.(2020).Management of Heart Failure Patients with COVID-19. A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology..European journal of heart failure,22,(6)
MLA：
Yuhui Zhang,et al."Management of Heart Failure Patients with COVID-19. A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology.".European journal of heart failure 22..6(2020):941-956
医学